< content="width=device-width, initial-scale=1.0"> From Bench to Bedside: Antisense Therapy | Neurology Department | U of U School of Medicine

From Bench to Bedside: Antisense Therapy

Some ASOs have already received approval by the FDA to use nusinersen--a splice switching ASO--to treat children with spinal muscular atrophy. Clinicians in the Department of Neurology played an important part in the early testing of nusinersen in the last decade.